Cited 2 times in
Optimal radiation dose for patients with one to three lymph node positive breast cancer following breast-conserving surgery and anthracycline plus taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김용배 | - |
dc.date.accessioned | 2023-08-09T02:47:59Z | - |
dc.date.available | 2023-08-09T02:47:59Z | - |
dc.date.issued | 2017-01 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/195848 | - |
dc.description.abstract | Background and purpose: This study was performed to determine optimal radiation dose in pN1 breast cancer patients who received breast conserving surgery (BCS) and anthracycline plus taxane (AT)-based chemotherapy. Materials and methods: Retrospective chart reviews were performed in 1,147 patients who were treated between January 2006 and December 2010. The impact of radiation dose on treatment outcomes was evaluated. Results: Median follow-up time was 66 months. The 5-year rate of disease-free survival (DFS) was 93.2%. Larger tumor size (> 20 mm), positive lymphovascular invasion, high histologic grade, and high ratio of positive nodes (> 0.1) were significantly associated with inferior DFS. By using the 4 factors related to DFS, patients were categorized into high-risk (with ≥ 3 factors) and low-risk (with < 3 factors) groups. In the high-risk group, higher radiation dose (> 60.3 GyEQD2) was significantly associated with better DFS than the lower dose (≤ 60.3 GyEQD2). However, the radiation dose did not impact DFS in the low-risk group. Conclusions: Dosing of radiation affects the outcome of post-BCS radiotherapy in pN1 breast cancer. Doses of over 60.3 GyEQD2 were associated with better outcome in the high-risk patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Impact Journals | - |
dc.relation.isPartOf | ONCOTARGET | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Anthracyclines / therapeutic use | - |
dc.subject.MESH | Antineoplastic Agents / therapeutic use | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / therapeutic use | - |
dc.subject.MESH | Breast Neoplasms / mortality | - |
dc.subject.MESH | Breast Neoplasms / pathology* | - |
dc.subject.MESH | Breast Neoplasms / radiotherapy* | - |
dc.subject.MESH | Bridged-Ring Compounds / therapeutic use | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Dose-Response Relationship, Radiation* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lymph Node Excision | - |
dc.subject.MESH | Lymph Nodes / pathology | - |
dc.subject.MESH | Lymphatic Metastasis / pathology | - |
dc.subject.MESH | Mastectomy, Segmental | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Radiation Dosage* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Taxoids / therapeutic use | - |
dc.subject.MESH | Young Adult | - |
dc.title | Optimal radiation dose for patients with one to three lymph node positive breast cancer following breast-conserving surgery and anthracycline plus taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiation Oncology (방사선종양학교실) | - |
dc.contributor.googleauthor | Haeyoung Kim | - |
dc.contributor.googleauthor | Won Park | - |
dc.contributor.googleauthor | Jeong Il Yu | - |
dc.contributor.googleauthor | Doo Ho Choi | - |
dc.contributor.googleauthor | Seung Jae Huh | - |
dc.contributor.googleauthor | Yeon-Joo Kim | - |
dc.contributor.googleauthor | Eun Sook Lee | - |
dc.contributor.googleauthor | Keun Seok Lee | - |
dc.contributor.googleauthor | Han-Sung Kang | - |
dc.contributor.googleauthor | In Hae Park | - |
dc.contributor.googleauthor | Kyung Hwan Shin | - |
dc.contributor.googleauthor | Kyubo Kim | - |
dc.contributor.googleauthor | Kyung Ran Park | - |
dc.contributor.googleauthor | Yong Bae Kim | - |
dc.contributor.googleauthor | Sung Ja Ahn | - |
dc.contributor.googleauthor | Jong Hoon Lee | - |
dc.contributor.googleauthor | Jin Hee Kim | - |
dc.contributor.googleauthor | Mison Chun | - |
dc.contributor.googleauthor | Hyung-Sik Lee | - |
dc.contributor.googleauthor | Jung Soo Kim | - |
dc.contributor.googleauthor | Jong-Young Lee | - |
dc.identifier.doi | 10.18632/oncotarget.12882 | - |
dc.contributor.localId | A00744 | - |
dc.relation.journalcode | J02421 | - |
dc.identifier.eissn | 1949-2553 | - |
dc.identifier.pmid | 27793036 | - |
dc.subject.keyword | breast neoplasms | - |
dc.subject.keyword | dose-response relationship | - |
dc.subject.keyword | prognosis | - |
dc.subject.keyword | radiotherapy | - |
dc.contributor.alternativeName | Kim, Yong Bae | - |
dc.contributor.affiliatedAuthor | 김용배 | - |
dc.citation.volume | 8 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 1796 | - |
dc.citation.endPage | 1804 | - |
dc.identifier.bibliographicCitation | ONCOTARGET, Vol.8(1) : 1796-1804, 2017-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.